Sun Pharma Advanced Research Company (SPARC) is eligible to receive $5 million upon achieving the regulatory milestones for the program developed using SPARC technology. Pursuant to the agreement entered between the parties, SPARC shall also be eligible for additional future milestones and royalties on net sales.
SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.